A new schedule of CHOP/Rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 8, 2005, Pages 627-636

  Olivieri, Attilio ^a   Lucesole, Moira ^a   Capelli, Debora ^a   Gini, Guido ^a   Montanari, Mauro ^a   Candela, Marco ^a   Troiani, Emanuela ^a   Scortechini, Ilaria ^a   Poloni, Antonella ^a   Leoni, Pietro ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Autologous stem cell transplantation; Failure; Immunotherapy; Lymphoma; Rituximab

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; AGED; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; LUNG TOXICITY; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE; VINCRISTINE;

EID: 22344447164     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.05.002     Document Type: Article

References (37)

1. J.M. Vose P.J. Bierman J.R. Anderson et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up Blood 15 1992 2142-2148
2. C.H. Weaver F. Appelbaum F.B. Petersen C.D. Buckner Follow-up report on the outcome of patients relapsing after autologous marrow transplantation for malignant lymphoma J Clin Oncol. 11 1993 812-813
3. A.S. Freedman D. Neuberg J.G. Gribben et al. High-dose chemoradiotherapy and anti B cell monoclonal antibody purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long time remission J Clin Oncol. 16 1998 13-18
4. M. De Lima K.W. van Besien S.A. Giralt et al. Bone marrow transplantation after failure of autologous transplant for non Hodgkin's lymphoma Bone Marrow Transplant. 19 1997 121-127
5. T. Tsai S. Goodman R. Saez et al. Allogenic bone marrow transplantation in patients who relapse after autologous transplantation Bone Marrow Transplant. 20 1997 859-863
6. J.P. Radich T. Gooley J.E. Sanders C. Anasetti T. Chauncey F.R. Appelbaum Second allogenic transplantation after failure of first autologous transplantation Biol Blood Marrow Transplant. 6 2000 272-279
7. R. Haas R. Mohle S. Fruhauf et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma Blood 83 1994 3787-3794
8. M.E. Reff K. Carner K.S. Chambers et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435-445
9. A.J. Grillo Lopez Rituximab: An insider's historical prospective Semin Oncol. 27 suppl 12 2000 9-16
10. P. McLaughlin F.B. Hagemeister A.J. Grillo-Lopez Rituximab in indolent lymphoma: The single-agent pivotal trial Semin Oncol. 26 suppl 14 1999 79-87
11. B. Coiffier C. Haioun N. Ketterer et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study Blood 92 1998 1927-1932
12. O.M. Howard J.G. Gribben D.S. Neuberg et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular responses are not predictive of progression free survival J Clin Oncol. 20 2002 1288-1294
13. A.M. Gianni S. Cortelazzo M. Magni M. Martelli Rituximab: Enhancing stem cell transplantation in mantle cell lymphoma Bone Marrow Transplant. 29 suppl 1 2002 S10-S13
14. M.S. Czuczman A.J. Grillo-Lopez C.A. White et al. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol. 17 1999 268-276
15. B. Coiffier E. Lapage J. Briere et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large cell lymphoma N Engl J Med. 346 2002 235-242
16. D. Flieger S. Renoth I. Beier T. Sauerbruch I. Schmidt-Wolf IDEC-C2B8 in CD20-expressing lymphoma cell lines. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody Cell Immunol. 204 2000 55-63
17. W. Wilson Chemotherapy sensitization by rituximab: Experimental and clinical evidence Semin Oncol. 27 6 suppl 12 2000 30-36
18. S. Wilson D. Hurst A. Yuen L. Gluck IL-2-mediated NK cell expansion correlates with clinical response to rituximab: Results of 2 phase I trials of the combination of IL-2 and rituximab Blood 98 2001 2525a
19. L.A. Bober M.J. Grace C. Pugliese-Sivo A. Rojas-Triana L.M. Sullivan S.K. Narula The effect of GM-CSF and G-CSF on human neutrophil function Immunopharmacology 29 1995 111-119
20. A. Nagler I. Shur V. Barak I. Fabian Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation Leuk Res. 20 1996 637-643
21. B. Stockmeyer D. Elsasser M. Dechant et al. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies J Immunol Methods 248 2001 103-111
22. P. Venugopal S. Sivaraman X. Huang et al. Upregulation of CD20 antigen expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines Blood 92 suppl 1 1998 1009
23. A. Olivieri M. Lucesole D. Capelli et al. GM-CSF addition to rituximab improves the response rate and survival in patients with non-Hodgkin's lymphoma refractory or relapsed after bone marrow transplantation Haematol. 86 suppl 10 2001 31
24. B.D. Cheson S.J. Horning B. Coiffier et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol. 17 1999 1244
25. R. Simon Optimal two stage designs for phase II clinical trials Control Clin Trials 10 1989 1-10
26. J.M. Vose B.K. Link M.L. Grossbard et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol. 19 2001 389-397
27. T. Kewalramani A.D. Zelenetz S.D. Nimer et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 103 2004 3684-3688
28. L.G. Lum The kinetics of immune reconstitution after human marrow transplantation Blood 69 1987 369-380
29. K. Van Besien K.A. Sobocinski P.A. Rowlings S.C. Murphy J.O. Armitage M.R. Bishop Allogenic bone marrow transplantation for low-grade lymphoma Blood 92 1998 1832-1836
30. P. Corradini C. Tarella A. Olivieri et al. Reduced intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies Blood 99 2002 75-82
31. K. Branson R. Chopra P.D. Kottaridis et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies J Clin Oncol. 20 2002 4022-4031
32. T. Kewalramani S.D. Nimer A.D. Zelenetz et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non Hodgkin's lymphoma Bone Marrow Transplant. 32 2003 673-679
33. D.E. Tsai H.C.F. Moore C.L. Hardy et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation Bone Marrow Transplant. 24 1999 521-526
34. A. Shimoni I. Hardan A. Avigdor et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high risk aggressive non Hodgkin's lymphoma Br J Haematol. 122 2003 457-464
35. A.P. Rapoport B. Meisenberg C. Sarkodee-Adoo et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy Bone Marrow Transplant. 29 2002 303-312
36. S.M. Horwitz R.S. Negrin K.G. Blume et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Blood 103 2004 777-783
37. T.A. Davies A.J. Grillo Lopez C.A. White et al. Final report on the safety and efficacy of retreatment with Rituximab for patients with non Hodgkin's lymphoma [abstract] Blood 94 10 1999 88a